Facilitated By

San Antonio Medical Foundation

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety, Tolerability, And Efficacy Of Cilofexor In Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Inactive

The primary objective of this study is to evaluate whether Cilofexor (CILO), (previously known as GS-9674) reduces the risk of fibrosis progression among non-cirrhotic subjects with Primary Sclerosing Cholangitis (PSC).

Collaborative Project
Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.